NASDAQ:PBYI Puma Biotechnology (PBYI) Stock Price, News & Analysis $2.25 -0.05 (-2.17%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$2.23▼$2.3550-Day Range$2.25▼$4.0352-Week Range$2.13▼$7.73Volume175,681 shsAverage Volume497,571 shsMarket Capitalization$110.36 millionP/E Ratio6.82Dividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Puma Biotechnology alerts: Email Address Puma Biotechnology MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside211.1% Upside$7.00 Price TargetShort InterestBearish11.45% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.27Based on 7 Articles This WeekInsider TradingSelling Shares$376,379 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.87 out of 5 starsMedical Sector360th out of 910 stocksPharmaceutical Preparations Industry158th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingPuma Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePuma Biotechnology has only been the subject of 1 research reports in the past 90 days.Read more about Puma Biotechnology's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.45% of the float of Puma Biotechnology has been sold short.Short Interest Ratio / Days to CoverPuma Biotechnology has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in Puma Biotechnology has recently increased by 4.71%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldPuma Biotechnology does not currently pay a dividend.Dividend GrowthPuma Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PBYI. Previous Next 2.4 News and Social Media Coverage News SentimentPuma Biotechnology has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Puma Biotechnology this week, compared to 2 articles on an average week.Search Interest4 people have searched for PBYI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Puma Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Puma Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $376,379.00 in company stock.Percentage Held by Insiders23.70% of the stock of Puma Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.29% of the stock of Puma Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Puma Biotechnology's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Puma Biotechnology are expected to remain at $0.25 per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Puma Biotechnology is 6.82, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.80.Price to Earnings Ratio vs. SectorThe P/E ratio of Puma Biotechnology is 6.82, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 112.46.Price to Book Value per Share RatioPuma Biotechnology has a P/B Ratio of 2.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Puma Biotechnology's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsNASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...Click here to learn more >>> About Puma Biotechnology Stock (NASDAQ:PBYI)Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.Read More PBYI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PBYI Stock News HeadlinesAugust 15, 2024 | insidertrades.comMichael Patrick Miller Sells 23,358 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) StockSeptember 4 at 12:32 AM | finance.yahoo.comPuma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 7, 2024 | Paradigm Press (Ad)Ex-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…September 3, 2024 | americanbankingnews.comQ1 2026 EPS Estimates for Puma Biotechnology, Inc. (NASDAQ:PBYI) Raised by AnalystAugust 30, 2024 | americanbankingnews.comQ4 2024 EPS Estimates for Puma Biotechnology, Inc. (NASDAQ:PBYI) Decreased by Zacks ResearchAugust 21, 2024 | theglobeandmail.comThe Future of Medicine: Key Biotech Stocks to WatchAugust 21, 2024 | theglobeandmail.comThe Future of Medicine: Key Biotech Stocks to Watch (OSTX, CRBP, PBYI, ATNM)August 15, 2024 | msn.comPuma Biotech confirms court ruling on patent invalidity, disagrees with verdictSeptember 7, 2024 | Paradigm Press (Ad)Ex-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…August 14, 2024 | msn.comPuma Biotechnology quickly drops after patents for Tagrisso ruled invalidAugust 14, 2024 | msn.comPuma Biotech drops after patents ruled invalid in fight with AstraZeneca over TagrissoAugust 9, 2024 | finance.yahoo.comPuma Biotechnology's (NASDAQ:PBYI) Earnings Offer More Than Meets The EyeAugust 3, 2024 | finance.yahoo.comAnalysts Have Been Trimming Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target After Its Latest ReportAugust 2, 2024 | markets.businessinsider.comPuma Biotechnology: Hold Rating Justified by Sales Concerns and Financial StrainAugust 2, 2024 | gurufocus.comQ2 2024 Puma Biotechnology Inc Earnings Call TranscriptAugust 1, 2024 | businesswire.comPuma Biotechnology Reports Second Quarter Financial ResultsJuly 26, 2024 | benzinga.comWhere Puma Biotechnology Stands With AnalystsJuly 18, 2024 | businesswire.comPuma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial ResultsSee More Headlines Receive PBYI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2024Today9/07/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PBYI CUSIPN/A CIK1401667 Webwww.pumabiotechnology.com Phone(424) 248-6500Fax424-248-6501Employees200Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+211.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.33 Trailing P/E Ratio6.82 Forward P/E Ratio9.00 P/E GrowthN/ANet Income$21.59 million Net Margins4.01% Pretax Margin4.59% Return on Equity18.36% Return on Assets4.13% Debt Debt-to-Equity Ratio0.90 Current Ratio1.32 Quick Ratio1.23 Sales & Book Value Annual Sales$235.60 million Price / Sales0.47 Cash Flow$0.63 per share Price / Cash Flow3.59 Book Value$1.12 per share Price / Book2.01Miscellaneous Outstanding Shares49,050,000Free Float36,806,000Market Cap$110.36 million OptionableOptionable Beta1.09 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Alan H. Auerbach (Age 54)Founder, Chairman, President, CEO & Secretary Comp: $1.3MMr. Maximo F. Nougues (Age 55)CFO & Principal Accounting Officer Comp: $716.2kMr. Douglas Hunt B.Sc. (Age 59)FRAPS, Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance & Law Officer Comp: $598kMr. Jeffrey Jerome Ludwig (Age 58)Chief Commercial Officer Comp: $792.57kMr. Mariann OhanesianSenior Director of Investor RelationsKey CompetitorsMarinus PharmaceuticalsNASDAQ:MRNSRAPT TherapeuticsNASDAQ:RAPTAkebia TherapeuticsNASDAQ:AKBAAltimmuneNASDAQ:ALTAcelyrinNASDAQ:SLRNView All CompetitorsInsiders & InstitutionsFrazier Life Sciences Management L.P.Bought 246,264 shares on 8/16/2024Ownership: 6.349%Millennium Management LLCSold 130,130 shares on 8/15/2024Ownership: 6.448%Affinity Asset Advisors LLCBought 250,000 shares on 8/15/2024Ownership: 0.510%The Manufacturers Life Insurance Company Bought 17,765 shares on 8/15/2024Ownership: 0.036%Squarepoint Ops LLCBought 10,757 shares on 8/14/2024Ownership: 0.146%View All Insider TransactionsView All Institutional Transactions PBYI Stock Analysis - Frequently Asked Questions How have PBYI shares performed this year? Puma Biotechnology's stock was trading at $4.33 at the beginning of the year. Since then, PBYI shares have decreased by 48.0% and is now trading at $2.25. View the best growth stocks for 2024 here. How were Puma Biotechnology's earnings last quarter? Puma Biotechnology, Inc. (NASDAQ:PBYI) issued its quarterly earnings results on Thursday, August, 1st. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. The biopharmaceutical company had revenue of $47.10 million for the quarter, compared to analyst estimates of $43.99 million. Puma Biotechnology had a trailing twelve-month return on equity of 18.36% and a net margin of 4.01%. Who are Puma Biotechnology's major shareholders? Top institutional investors of Puma Biotechnology include Millennium Management LLC (6.45%), Frazier Life Sciences Management L.P. (6.35%), Acadian Asset Management LLC (4.04%) and Renaissance Technologies LLC (3.63%). Insiders that own company stock include Alan H Auerbach, Maximo F Nougues, Jeffrey Jerome Ludwig, Alvin F Wong, Douglas M Hunt, Michael Patrick Miller and Troy Edward Wilson. View institutional ownership trends. How do I buy shares of Puma Biotechnology? Shares of PBYI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Puma Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL) and (KITE) (KITE). This page (NASDAQ:PBYI) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Puma Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
